Associated Papers
Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer.
Chaubal R et al.
Breast Cancer Research and Treatment, 2025
40652157 (PubMed )
Supplement: 10549_2025_7759_MOESM1_ESM.xlsx › stable6
Evolutionary history of adenomas to colorectal cancer in FAP families.
Yang C et al.
Frontiers in Genetics, 2024
39021676 (PubMed )
Supplement: DataSheet1.ZIP › Somatic › 2017-2279A1.xls › SNVIndel
Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma.
Leko V et al.
Journal for Immunotherapy of Cancer, 2021
34266885 (PubMed )
Supplement: jitc-2021-002882supp001.pdf
Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma.
Wang A et al.
Nature Communications, 2018
29497050 (PubMed )
Supplement: 41467_2018_3276_MOESM5_ESM.xlsx › ___1
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.
Antonello ZA et al.
Oncotarget, 2017
29156680 (PubMed )
Supplement: oncotarget-08-84743-s004.xls › Sheet1
Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer.
Ma P et al.
Nature Communications, 2017
29018192 (PubMed )
Supplement: 41467_2017_963_MOESM1_ESM.pdf
Select a paper to view details